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ABSTRACT
Objective To explore mortality risk factors for patients 
hospitalised with COVID- 19 in a critical care unit (CCU) or a 
hospital care unit (HCU).
Design Retrospective cohort analysis using the French 
national (Programme de médicalisation des systèmes 
d’information) database.
Setting Any public or private hospital in France.
Participants 98 366 patients admitted with COVID- 19 for 
more than 1 day during the first semester of 2020 were 
included. The underlying conditions were retrieved for all 
contiguous stays.
Main outcome measures In- hospital mortality and 
associated risk factors were assessed using frailty Cox 
models.
Results Among the 98 366 patients included, 25 765 
(26%) were admitted to a CCU. The median age was 66 
(IQR: 55–76) years in CCUs and 74 (IQR: 57–85) years in 
HCUs. Age was the main risk factor of death in both CCUs 
and HCUs, with adjusted HRs (aHRs) in CCUs increasing 
from 1.60 (95% CI 1.35 to 1.88) for 46 to 65 years to 8.17 
(95% CI 6.86 to 9.72) for ≥85 years. In HCUs, the aHR 
associated with age was more than two times higher. The 
gender was not significantly associated with death, aHR 
1.03 (95% CI 0.98 to 1.09, p=0.2693) in CCUs. Most of the 
underlying chronic conditions were risk factors for death, 
including malignant neoplasm (CCU: 1.34 (95% CI 1.25 to 
1.43); HCU: 1.41 (95% CI 1.35 to 1.47)), cirrhosis without 
transplant (1.41 (95% CI 1.22 to 1.64); 1.27 (95% CI 1.12 
to 1.45)) and dementia (1.30 (95% CI 1.16 to 1.46); 1.07 
(95% CI 1.03 to 1.12)).
Conclusion This analysis confirms the role of age as 
the major risk factor of death in patients with COVID- 19 
irrespective to admission to critical care and therefore 
supports the current vaccination policies targeting older 
individuals.
INTRODUCTION
Unprecedented worldwide efforts have led to 
the development of several vaccines against 
the SARS- CoV- 2 infection and its associated 
disease (COVID- 19) in less than a year.1–3 This 
achievement is an important first step towards 
controlling the spread of the SARS- CoV- 2 
pandemic. Further challenges remain in the 
production of sufficient doses of vaccine and 
their administration to more than half of 
the world population to reach ‘population 
immunity’.4 This goal will be impossible to 
achieve in the short term given the limited 
resources to produce and administer the 
vaccine. An alternative, such as the vaccina-
tion of targeted populations with a higher risk 
of severe outcomes, has already been imple-
mented in many countries.
Studies and meta- analyses have reported 
mortality rates for patients admitted with 
COVID- 19 to range from 2% to 39%,5–7 
depending on the country and admission 
Key messages
 ► Observational studies have identified age, gender 
and comorbidities to be the main risk factors of 
death for patients hospitalised with COVID- 19, but 
most of them did not differentiate patients admitted 
to a critical care unit from those who were not.
 ► Analyses pooling data of patients admitted to a crit-
ical care unit and those who were not might lead 
to biased estimates of risks with substantial con-
sequences for prevention strategies such as vac-
cination targeting populations with a higher risk of 
severe outcomes.
 ► This study, one of the largest nationwide COVID- 19 
cohorts, confirms the role of age as the major risk 
factor of death and show that mortality risks associ-
ated with comorbidities differ between patients ad-
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to critical care units (CCUs).5 Reported mortality risk 
factors are old age, chronic major comorbidities and 
male sex.7 8 Most of the studies included in the published 
meta- analyses came from Asia and, except for age and 
gender, the impact of other risk factors, such as comor-
bidities, varied between them.5 Their findings are key 
to guiding target population vaccination strategies and 
the better they reflect reality, the better they can support 
health policy decisions.
In France, the epidemic started in late February 2020 
and by late March 2021, more than 4.3 million people 
had been infected for approximately 93 900 deaths.9 The 
first epidemic wave started at the end of February 2020, 
peaked in April 2020 and ended towards the end of June 
2020. The country is struggling to control the epidemic 
with individual physical barrier measures and a series 
of general population lockdowns, with limited efficacy. 
Vaccination against SARS- CoV- 2 is being progressively 
implemented, but reliable evidence is needed to support 
decisions about the populations to target. Studies have 
reported high mortality rates among men and older 
patients hospitalised with COVID- 19.10 11 Few studies 
have assessed clinical risk factors for mortality in patients 
hospitalised with COVID- 19 in France, particularly those 
stratified according to admission to critical care.
We aimed to explore demographic and clinical risk 
factors associated with in- hospital mortality in a nation-
wide cohort of patients admitted with COVID- 19 in any 
hospital in France during the first wave of the pandemic.
METHODS
Study design and French national hospital database
A retrospective cohort study was performed using the 
French national Programme de médicalisation des systèmes 
d’information (PMSI) database.12 The PMSI was inspired 
by the diagnosis- related group classification system 
developed in the USA in the 1980s. The PMSI is a large, 
relatively exhaustive, national database that has gath-
ered data transmitted monthly by all public and private 
hospitals in France since 1997. Initially, the PMSI served 
to analyse hospital activity and guide healthcare policy. 
Since 2004, the PMSI has been used to guide health 
resource allocation following the implementation of an 
activity- based hospital funding policy. Administrative and 
medical data are recorded at discharge from hospital for 
all patient stays. Diagnoses are coded using the Interna-
tional Classification of Diseases, 10th revision (ICD- 10), 
and procedures performed during hospitalisation are 
coded according to the Common French Classification of 
Medical Acts. After anonymisation, the data are uploaded 
by each hospital to a secure national platform, consti-
tuting the PMSI national database.
Participants
All patients admitted to any hospital for COVID- 19 
between 1 January and 30 June 2020 and discharged at 
the latest on 30 September 2020 were included, regardless 
of their age. We selected patients whose care sequence 
contained at least one of the following ICD- 10 diagnosis 
codes for COVID- 19, adapted from those defined by 
the WHO: U07.1, U07.10, U07.11, U07.12, U07.14 and 
U07.15.13 The care sequence for a patient was defined 
as the sum of all contiguous hospital stays (with less than 
1 day in between). The starting date of the care sequence 
was the admission date for the first stay, and the end date 
was the date of discharge or death. We excluded care 
sequences lasting less than 1 day unless the patient died. 
Only the first care sequence per patient was considered.
Outcome
The primary outcome was in- hospital mortality defined 
as death occurring during hospital stay. In- hospital 
mortality was collected using a variable of the PMSI 
describing mortality and the destination at discharge.
Covariates
The following variables were assessed for each included 
patient: age, gender, body mass index (BMI), underlying 
illnesses, admission to a CCU or hospital care unit (HCU) 
and death. Critical care regroups all levels of intensive 
care units. Patients treated in both a CCU and HCU were 
considered to be in a CCU.
Age groups were categorised as follows: <18, 18–45, 
46–65, 66–70, 71–84 and ≥85 years The age categories 
were defined based on literature review strengthened 
by Chi- square Automatic Interaction Detector method 
(SIPINA software V.3.12).14 The BMI was defined by 
ICD- 10 codes (online supplemental table S1) and catego-
rised as: <30, 30–39 and ≥40 kg/m².
A team of physicians experienced in medical infor-
mation reviewed the ICD- 10 codes and classified under-
lying illnesses as chronic conditions (ascertained during 
the entire care sequence or within any previous hospi-
talisation 2 years before admission) or acute conditions 
(ascertained during the current entire care sequence). 
The definitions and ICD- 10 codes used to specify 
comorbidities are listed in online supplemental table 
S1. Chronic conditions included hypertension, chronic 
cardiac disease, diabetes (type 1 and 2), chronic kidney 
disease, asthma, chronic pulmonary disease, malig-
nant neoplasm, dementia, solid organ transplant, HIV/
AIDS, dyslipidaemia, cirrhosis without transplant, coro-
nary artery disease and history of stroke. The Charlson 
comorbidity index was computed as global measure of 
comorbidity.15 Acute conditions included acute pulmo-
nary failure, acute respiratory distress syndrome, acute 
pulmonary infection (excluding viral infections), shocks 
(including hypovolaemic shock, cardiogenic shock and 
septic shock), myocardial infarction, acute pulmonary 
embolism, thrombophlebitis, acute liver failure and 
acute kidney injury.
COVID- 19 cases were classified based on ICD- 10 codes 
as asymptomatic (U07.12), with respiratory symptoms 
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(U07.14 or U07.15). U07.10, U07.12 and U07.14 were 
used to define laboratory- confirmed COVID- 19 cases and 
U07.11 and U07.15 for clinically or radiologically diag-
nosed cases. A code hierarchy was used if there was more 
than one U07.X code during the same care sequence as 
follows: U0710 >U0714>U0712>U0711>U0715.
Statistical analysis
Continuous variables are described as medians and IQR 
and categorical variables as frequencies and percentages.
The Kaplan- Meier method was used to estimate the 
cumulative probability of death stratified by age group, 
gender and admission or not to a CCU. As mentioned 
previously, the care sequences had to end by 30 September 
to allow for a relatively complete follow- up for the 
patients included in this study. The duration of follow- up 
was the difference between the hospital admission date 
and discharge or death date. Discharged patients were 
considered to no longer be at risk of in- hospital death.
Multivariate Cox frailty models, using the last depart-
ment of the hospitalisation as a random intercept, were 
used to investigate risk factors associated with in- hospital 
mortality. The analysis was stratified according to admis-
sion to a CCU or HCU, with separate presentation of the 
results. HIV/AIDS and the Charlson comorbidity index 
were not included in multivariate analyses, the former 
because of a few patients concerned and the latter to 
avoid colinearity with the comorbidities. Covariates were 
retained in the final model if significant (α≤5%). Gender, 
chronic cardiac disease and solid organ transplant were 
forced into the final model. First- order interactions 
between admission to CCU and either age, gender or 
BMI were investigated and proportional hazards assump-
tions explored.
Sensitivity analyses were performed including alterna-
tive modelling and subgroups analyses: (1) alternative 
modelling using logistic regressions (online supple-
mental table S3); (2) frailty Cox model excluding length 
of stay (LOS) outliers defined as LOS longer than 60 
days (online supplemental table S4); and (3) frailty Cox 
model with age in continuous variable (online supple-
mental table S5).
All tests were two sided. Analyses were performed using 
SAS Enterprise Guide V.8.3 software and R V.3.5.2 (pack-
ages: survival, survminer, forestplot).
Patient and public involvement
Neither patients nor the public were involved in the 
design, conduct or reporting of this study. Anonymised 
patient discharge data were used to address a national 
research priority question in the context of urgency and 
rapid progression of the COVID- 19 pandemic.
RESULTS
Study population
Among the 111 940 patients hospitalised with COVID- 19 
in France between January and June 2020, 98 366 (88%) 
were included in this study. In total, 13 574 (12%) 
patients who were discharged alive after a LOS of <1 day 
were excluded. Among the patients included, 82 764 
(84%) had a sequence of care with one hospital stay and 
15 602 (16%) had more than one hospital stay (figure 1).
Overall, 25 765 (26%) were admitted to a CCU at any 
time, with a median care sequence LOS of 15 days (IQR: 
Figure 1 Study patient selection flow chart. The selection process of the patients included in our analysis is presented. 
The care sequence was defined as the sum of all contiguous hospital stays (with less than 1 day in between). Patients were 
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8–28) and 72 601 (74%) were admitted to a HCU with a 
median LOS of 8 days (IQR: 4–13) (table 1). Among the 
patients admitted to a CCU, 18 158 (70%) stayed in one 
hospital and 7607 (30%) were hospitalised in more than 
one hospital (figure 1).
Demographic and clinical characteristics
The demographic and clinical characteristics of the 
patients are presented in table 2.
In this study, 54% of the hospitalised patients were 
men, with a higher proportion of men admitted to 
CCUs than HCUs (65% vs 50%). The median age was 
66 years (IQR: 55–76) for the patients in CCUs and 74 
years (IQR: 57–85) for those in HCUs. Patients in CCUs 
were younger, with a higher proportion <70 years of age 
(61% vs 44%) and a lower proportion of patients aged 85 
years and older (9% vs 27%). Approximately 18% of the 
patients in CCUs had a BMI >30 kg/m² compared with 
8% in HCUs.
Among the 98 366 patients, 87 940 (89%) had respi-
ratory symptoms of COVID- 19. The proportion of respi-
ratory presentation was significantly higher for patients 
admitted to CCUs (94% vs 88%). The proportion of 
patients with at least one chronic underlying condition 
was 89%. A higher proportion of patients in CCUs had a 
comorbidity score ≥3 for the Charlson comorbidity index 
(23% vs 18%). The most common chronic underlying 
conditions were hypertension (47%), diabetes (24%), 
chronic cardiac disease (16%) and coronary artery 
disease (14%). Patients in CCUs had a significantly higher 
proportion of chronic underlying conditions, except 
for malignant neoplasm, chronic kidney disease and 
dementia. Fewer patients with dementia were admitted 
to CCUs (4% vs 14%). The most common underlying 
Table 1 Survival and follow- up characteristics of 98 366 patients hospitalised with COVID- 19 in France between 1 January 
and 30 June 2020 (data are presented as n (%) unless otherwise indicated)
Overall
(n=98 366)
Patients admitted to a CCU
(n=25 765)
Patients admitted to an 
HCU
(n=72 601) P value
Median length of stay in days 
(IQR)
9 (4–16) 15 (8–28) 8 (4–13) <0.0001
Median survival time in days 
(95% CI*)
Overall 61 (59 to 64) 77 (72 to 83) 48 (46 to 52) <0.0001
By gender and age
  Male
  <18 – – –
  18–45 142 (125 to NA) 142 (125 to NA) 81 (62 to NA)
  46–65 127 (109 to NA) 154 (119 to NA) 72 (63 to NA)
  66–70 77 (67 to 93) 82 (71 to 107) 61 (48 to 85)
  71–84 41 (38 to 43) 45 (41 to 50) 37 (34 to 41)
  ≥85 23 (22 to 24) 22 (19 to 25) 23 (22 to 25)
Female
  <18 – – –
  18–45 – – 84 (68 to NA)
  46–65 122 (94 to NA) 122 (94 to NA) 83 (64 to NA)
  66–70 87 (77 to NA) 89 (72 to NA) 81 (65 to NA)
  71–84 57 (50 to 67) 53 (47 to 67) 57 (49 to 72)
  ≥85 43 (41 to 47) 32 (27 to 40) 46 (43 to 52)
Survival time
  ≤60 days 96 466 (98.1) 24 267 (94.2) 72 199 (99.4)
  >60 days 1 900 (1.9) 1 498 (5.8) 402 (0.6)
Status at the end of follow- up
  Discharged 79 920 (81.2) 19 584 (76.0) 60 336 (83.1)
  Died in hospital 18 446 (18.8) 6 181 (24.0) 12 265 (16.9)
*CIs were obtain from R survfit function using log transformation.
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Table 2 Demographic characteristics and underlying conditions of 98 366 patients hospitalised with COVID- 19 in France 
between 1 January and 30 June 2020 (data are presented as n (%) unless otherwise indicated)
Overall
(n=98 366)
Patients admitted to a 
critical care unit
(n=25 765)
Patients admitted to a 
hospital care unit
(n=72 601) P value
Age, years <0.0001
  Median (IQR) 71 (56–83) 66 (55–76) 74 (57–85)
  <18 1571 (1.6) 599 (2.3) 972 (1.3)
  18–45 11 065 (11.2) 2527 (9.8) 8538 (11.8)
  46–65 19 579 (19.9) 6733 (26.1) 12 846 (17.7)
  66–70 15 783 (16.0) 5997 (23.3) 9786 (13.5)
  71–84 28 249 (28.7) 7490 (29.1) 20 759 (28.6)
  ≥85 22 119 (22.5) 2419 (9.4) 19 700 (27.1)
Gender <0.0001
  Female 45 444 (46.2) 8898 (34.5) 36 546 (50.3)
  Male 52 922 (53.8) 16 867 (65.5) 36 055 (49.7)
Body mass index, kg/m² <0.0001
  <30 87 959 (89.4) 21 183 (82.2) 66 776 (92.0)
  30–39 8316 (8.5) 3655 (14.2) 4661 (6.4)
  ≥40 2091 (2.1) 927 (3.6) 1164 (1.6)
Clinical presentation <0.0001
  Asymptomatic 4335 (4.4) 496 (1.9) 3839 (5.3)
  Respiratory symptoms 87 940 (89.4) 24 328 (94.4) 63 612 (87.6)
  Other symptoms 6091 (6.2) 941 (3.7) 5150 (7.1)
Chronic underlying conditions
Charlson comorbidity index <0.0001
  0 42 366 (43.1) 9649 (37.5) 32 717 (45.1)
  1–2 37 077 (37.7) 10 182 (39.5) 26 895 (37.0)
  ≥3 18 923 (19.2) 5934 (23.0) 12 989 (17.9)
Hypertension <0.0001
  No 51 891 (52.8) 12 718 (49.4) 39 173 (54.0)
  Yes 46 475 (47.2) 13 047 (50.6) 33 428 (46.0)
Chronic cardiac disease <0.0001
  No 82 558 (83.9) 21 405 (83.1) 61 153 (84.2)
  Yes 15 808 (16.1) 4360 (16.9) 11 448 (15.8)
Coronary artery disease <0.0001
  No 84 568 (86.0) 21 674 (84.1) 62 894 (86.6)
  Yes 13 798 (14.0) 4091 (15.9) 9707 (13.4)
Diabetes (types 1 and 2) <0.0001
  No 74 397 (75.6) 18 462 (71.7) 55 935 (77.0)
  Yes 23 969 (24.4) 7303 (28.3) 16 666 (23.0)
Chronic kidney disease 0.0020
  No 85 167 (86.6) 22 453 (87.1) 62 714 (86.4)
  Yes 13 199 (13.4) 3312 (12.9) 9887 (13.6)
Asthma <0.0001
  No 93 790 (95.3) 24 414 (94.8) 69 376 (95.6)
  Yes 4576 (4.7) 1351 (5.2) 3225 (4.4)
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Patients admitted to a 
critical care unit
(n=25 765)
Patients admitted to a 
hospital care unit
(n=72 601) P value
  No 88 708 (90.2) 23 020 (89.3) 65 688 (90.5)
  Yes 9658 (9.8) 2745 (10.7) 6913 (9.5)
Malignant neoplasm <0.0001
  No 86 056 (87.5) 22 778 (88.4) 63 278 (87.2)
  Yes 12 310 (12.5) 2987 (11.6) 9323 (12.8)
Dementia <0.0001
  No 87 104 (88.6) 24 758 (96.1) 62 346 (85.9)
  Yes 11 262 (11.4) 1007 (3.9) 10 255 (14.1)
Solid organ transplant <0.0001
  No 97 171 (98.8) 25 265 (98.1) 71 906 (99.0)
  Yes 1195 (1.2) 500 (1.9) 695 (1.0)
HIV/AIDS 0.0018
  No 97 727 (99.4) 25 563 (99.2) 72 164 (99.4)
  Yes 639 (0.6) 202 (0.8) 437 (0.6)
Dyslipidaemia <0.0001
  No 87 410 (88.9) 22 264 (86.4) 65 146 (89.7)
  Yes 10 956 (11.1) 3501 (13.6) 7455 (10.3)
Cirrhosis without transplant <0.0001
  No 96 841 (98.4) 25 283 (98.1) 71 558 (98.6)
  Yes 1525 (1.6) 482 (1.9) 1043 (1.4)
History of stroke
  No 92 174 (93.7) 24 199 (93.9) 67 975 (93.6) 0.0950
  Yes 6192 (6.3) 1566 (6.1) 4626 (6.4)
Acute underlying conditions
Acute pulmonary failure <0.0001
  No 67 549 (68.7) 10 522 (40.8) 57 027 (78.5)
  Yes 30 817 (31.3) 15 243 (59.2) 15 574 (21.5)
Acute respiratory distress syndrome <0.0001
  No 86 724 (88.2) 16 101 (62.5) 70 623 (97.3)
  Yes 11 642 (11.8) 9664 (37.5) 1978 (2.7)
Acute pulmonary infection* <0.0001
  No 83 413 (84.8) 18 232 (70.8) 65 181 (89.8)
  Yes 14 953 (15.2) 7533 (29.2) 7420 (10.2)
Shock† <0.0001
  No 92 732 (94.3) 20 649 (80.1) 72 083 (99.3)
  Yes 5634 (5.7) 5116 (19.9) 518 (0.7)
Myocardial infarction <0.0001
  No 97 712 (99.3) 25 379 (98.5) 72 333 (99.6)
  Yes 654 (0.7) 386 (1.5) 268 (0.4)
Acute pulmonary embolism <0.0001
  No 94 331 (95.9) 23 596 (91.6) 70 735 (97.4)
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acute conditions were acute pulmonary failure (31%), 
acute pulmonary infection (15%), acute kidney injury 
(13%) and acute respiratory distress syndrome (12%).
Follow-up and survival
Overall, 79 920 (81%) patients were alive at discharge 
and 18 446 (19%) died in hospital. The cumulative 
proportion of death was higher for patients admitted to 
CCUs than those to HCUs (24% vs 17%) (table 1). The 
proportion of deaths was the highest (26%) for those who 
were admitted to a CCU and stayed in only one hospital 
(figure 1). Median survival was 77 days (95% CI 72 to 83) 
and 48 days (95% CI 46 to 52) for patients in CCUs and 
HCUs, respectively (table 1). About 6% of the patients 
admitted to CCU had a survival time >60 days versus 0.6% 
for those admitted to HCU.
Older men had a lower probability of survival. The 
probability of survival decreased with increasing age for 
Overall
(n=98 366)
Patients admitted to a 
critical care unit
(n=25 765)
Patients admitted to a 
hospital care unit
(n=72 601) P value
  No 96 057 (97.7) 24 413 (94.8) 71 644 (98.7)
  Yes 2309 (2.3) 1352 (5.2) 957 (1.3)
Acute liver failure <0.0001
  No 97 517 (99.1) 25 183 (97.7) 72 334 (99.6)
  Yes 849 (0.9) 582 (2.3) 267 (0.4)
Acute kidney injury <0.0001
  No 85 545 (87.0) 19 382 (75.2) 66 163 (91.1)
  Yes 12 821 (13.0) 6383 (24.8) 6438 (8.9)
*Acute pulmonary infection, excluding viral infections.
†Shock includes hypovolaemic shock, cardiogenic shock or infectious shock.
Table 2 Continued
Figure 2 Probability of survival according to gender and admission to a critical care or hospital care unit Kaplan- Meier 
estimates for six age groups (<18, 18–45, 46–65, 66–70, 71–84 and ≥85) by sex and admission to critical care unit. (A) 
Survival curves by age group for men admitted to a critical care unit. (B) Survival curves by age group for men admitted to a 
hospital care unit. (C and D) Survival curves for women admitted to a critical care unit and those admitted to a hospital care 
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patients in CCUs, especially men (figure 2A,C). Very 
few deaths occurred for patients <18 years old, with no 
difference according to gender. For men admitted to 
CCUs, median survival decreased from 154 days for the 
46–65 years group to 22 days (IQR: 19–25) for those ≥85 
years of age. For women admitted to CCUs, median 
survival decreased from 122 days in the 46–65 years 
group to 32 days (IQR: 27–40) for those ≥85 years of age 
(table 1).
Among patients admitted to HCUs, survival was less 
correlated with age, particularly for men and women ≥85 
years of age, who had the lowest probability of survival 
(figure 2B,D). Men had a median survival of 23 days 
(IQR: 22–25), whereas that of women was 46 days (IQR: 
43–52). For women aged below 70 years, median survival 
was essentially the same: approximately 80 days (table 1).
Risk factors of mortality
Cox proportional adjusted HRs (aHRs) for the varia-
bles that remained in the final multivariable model are 
presented in figure 3. Results of univariable and initial 
multivariable models are available in online supple-
mental table S2.
Age was a strong risk factor associated with death for 
patients hospitalised with COVID- 19 in both CCUs and 
HCUs. The aHR for death varied from 1.60 (95% CI 
1.35 to 1.88) for patients aged 46–65 years to 8.17 (95% 
CI 6.86 to 9.72) for those aged 85 years and above for 
patients in CCUs. The aHR of death associated with age 
was more than two times higher for patients admitted to 
HCUs than those admitted to CCUs, varying from 3.29 
(95% CI 2.48 to 4.37) in the 46–65 years group to 18.21 
(95% CI 13.90 to 23.86) for those ≥85 years of age.
Gender was not significantly associated with death for 
patients admitted to CCUs in multivariable analysis, aHR 
1.03 (95% CI 0.98 to 1.09, p=0.2504). The main chronic 
conditions associated with death were cirrhosis without 
transplant, aHR 1.41 (95% CI 1.21 to 1.64, p<0.001), 
malignant neoplasm, 1.34 (95% CI 1.25 to 1.43), p<0.001, 
and dementia, 1.30 (95% CI 1.16 to 1.46, p<0.001). A 
BMI ≥40 kg/m², history of stroke, coronary artery disease, 
diabetes and chronic pulmonary disease were also risk 
factors of death, with moderate aHRs. Hypertension was 
associated with a decreased risk of death, aHR 0.81 (95% 
CI 0.76 to 0.85, p<0.001). The main acute conditions 
associated with death were shock, aHR 1.64 (95% CI 1.54 
Figure 3 Factors associated with in- hospital mortality stratified by admission to critical care in a cohort of patients 
hospitalised with COVID- 19 in France between 1 January and 30 June 2020 forest plot showing Cox proportional 
multivariable adjusted HRs (aHRs) in the subpopulation of patients admitted to a critical care unit, represented by black 
squares, and those admitted to a hospital care unit, represented by blue circles. The bars on each side of the squares or 
circles represent the 95% CIs. The aHRs and corresponding 95% CI are shown on a log- scale on the plot. The aHRs are 
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to 1.74, p<0.001), acute respiratory distress syndrome, 
1.60 (95% CI 1.50 to 1.70, p<0.001), acute liver failure, 
1.54 (95% CI 1.37 to 1.74, p<0.001)) and acute kidney 
injury, 1.34 (1.26 to 1.42, p<0.001)) (figure 3).
Among patients admitted to HCUs, men had a higher 
risk of death, aHR: 1.28 (95% CI 1.23 to 1.33, p<0.001). As 
for patients admitted to CCUs, the main chronic condi-
tions associated with death were malignant neoplasm, 
aHR 1.41 (95% CI 1.35 to 1.4, p<0.001) and cirrhosis 
without transplant, 1.27 (95% CI 1.12 to 1.45, p<0.001). 
A history of stroke, chronic kidney disease and dementia 
were factors associated with a moderate risk of death. 
Diabetes and chronic pulmonary disease were not signifi-
cantly associated with death. Asthma was associated with 
a reduced risk of death, aHR 0.76 (95% CI 0.68 to 0.85, 
p<0.001). Acute respiratory distress syndrome, aHR 3.95 
(95% CI 3.73 to 4.18, p<0.001), acute pulmonary failure, 
3.16 (95% CI 3.05 to .28, p<0.001) and shock 2.91 (95% 
CI 2.63 to 3.23, p<0.001) were associated with a higher 
risk of death (figure 3).




In this study, we investigated in- hospital mortality and the 
associated risk factors in a large cohort of patients hospi-
talised with COVID- 19 in France. Age was the major inde-
pendent risk factor of death for both patients in CCUs 
and those in HCUs. However, patients in HCUs had a 
higher risk of death associated with age than those in 
CCUs. Mortality increased was strongly correlated with 
age for men and women in CCUs and men ≥85 years of 
age had the highest probability of death. Among patients 
admitted to HCUs, mortality was less correlated with age, 
especially for women.
Comparison with other studies
We stratified our analysis according to CCU or HCU 
admission, as the patients and care differ between CCUs 
and HCUs. This was illustrated by the larger survival 
times for patients in CCU compared with those in HCU, 
consequence of a higher proportion of ‘outlier’ survival 
times (>60 days) in CCU and selection bias regarding age 
and dementia. Older patients with a higher proportion 
of dementia were less likely admitted to CCU.
The proportion of patients admitted to CCUs (26% in 
our study) was in the range of that previously reported.8 10 16 
We found a higher proportion of men admitted to CCUs, 
consistent with studies in the UK reporting 67%–70% 
men in intensive care.17 18 As shown previously, men 
hospitalised with COVID- 19 were more likely to have 
comorbidities and have a higher risk of worse outcomes; 
thus, they were logically more likely to be admitted to 
CCUs.16 19 20 We found a lower proportion of patients with 
dementia in CCUs, as they are more often ≥85 years of 
age, consistent with the findings of a study in a centre 
within the highest health and wealth band in the UK.18 
The risk–benefit balance of admitting older patients with 
dementia to CCUs is a larger and openly debated ques-
tion, although it is more challenging in the context of 
the COVID- 19 epidemic. Similarly to studies in the UK, 
we found a lower proportion of malignant neoplasm and 
chronic kidney disease in patients admitted to CCUs.17 18
Patients admitted to CCUs had more severe acute 
conditions and a higher cumulative mortality rate. 
Consistent with previous studies, age was the stron-
gest risk factor for death for patients hospitalised with 
COVID- 19.10 16 19–21 The risk of death associated with age 
was more than two times higher for patients admitted to 
HCUs than those admitted to CCUs. Patients admitted 
to CCUs were kept alive and followed much longer in 
care. Mortality was markedly correlated with age among 
both men and women in CCUs. A previous study demon-
strated an exponential relationship between mortality 
and age in patients with COVID- 19.22 Gender was not 
significantly associated with death in CCUs, whereas 
men had a higher risk of death in HCUs. Although the 
results of published studies were not stratified according 
to admission to CCUs,16 19–21 23 a study in New York also 
found no association between mortality and gender after 
adjusting for vital signs and laboratory parameters.21 The 
cumulative mortality rate in our study was in the range of 
those of other studies.10 16 21
Published studies have reported several comorbidities 
to be risk factors of mortality for patients hospitalised with 
COVID- 19.8 10 16 17 19–21 We found a higher risk of mortality 
for patients with malignant neoplasm, cirrhosis without 
transplant and dementia in both CCUs and HCUs. These 
results are consistent with previous findings.10 16 20 24 
Dementia had a higher effect on mortality for patients 
admitted to CCUs than those admitted to HCUs. The 
management of COVID- 19 for patients with dementia is 
an issue that requires further focused analyses.25 26 Defini-
tions of comorbidities vary widely, which made it difficult 
to interpret comparisons across studies.
In addition to the age and comorbidities, other factors 
associated with mortality such as early access to care and 
treatment have been explored.27 28 Data about the time 
between onset of illness and hospitalisation were not 
available. Thus, we were not able to account for access 
to care at the individual level, but we took into account 
the variability of care at the departmental level through 
random effects in modelling. The analysis stratification 
according to admission to CCU contributes to control 
potential biases due to differences in care delivery, 
assuming that patients admitted to CCU benefit from 
recent treatment regimens such as steroids, tocilizumab 
or non- invasive ventilation.
Strengths and limitations of study
The strengths of this analysis were its reliance on the 
analysis of the entire sequence of care and stratification 
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studies,11 19 we did not analyse the hospital stay within 
one hospital but used the complete sequence of hospi-
talisation. Indeed 16% of patients were transferred to at 
least one other hospital. If this had not been done, we 
would have underestimated the mortality rate and LOS 
and introduced a bias in the risk factor analysis. In addi-
tion, stratification of the results according to CCU admis-
sion was crucial, as we show that the risk of death and its 
risk factors were different according to the type of unit of 
hospitalisation.
Our study had several limitations. First, we used the 
PMSI database, which is a large nationwide database 
with a risk of variability in coding of the underlying 
conditions. To mitigate this risk, we relied on a team 
of physicians with experience in medical information 
who selected the ICD- 10 codes included in our analysis, 
taking the coding rules and the reliability of the infor-
mation into account. To enhance the completeness of 
the description of chronic underlying conditions, we 
expanded our research to 2 years before the hospital-
isation with COVID- 19. Second, as we did not have the 
date linked to the codes, we were unable to ascertain the 
precise moment of occurrence of the acute conditions. 
Combining the PMSI and other local or national health 
databases may be interesting to explore the relationship 
between mortality and acute event leading to admission 
or treatments. Third, we did not have direct measures 
of severity. Thus, we stratified our analysis according 
to admission to critical care. In addition, we used the 
Charlson comorbidity index as a proxy of disease burden. 
We did not include this index in the multivariate anal-
ysis as we were interested in exploring the independent 
effect of several comorbidities on mortality. Fourth, we 
might have underestimated or overestimated mortality, 
as we included patients with an ICD- 10 of COVID- 19, 
irrespective of the reason of their admission. However, 
our study focused on the first epidemic wave of SARS- 
CoV- 2 in France, during which most of the screening 
tests were carried out on symptomatic patients. Sensitivity 
analysis in which we varied the COVID- 19 case definition 
resulted in an insignificant impact on our findings. Fifth, 
as we included the first care sequence per patient, we 
did not consider in- hospital deaths occurring in a later 
care sequence. This could have led to biased results if 
patients with multiple care sequences differed in terms 
of mortality risk factors from those with a unique care 
sequence.
CONCLUSIONS AND POLICY IMPLICATIONS
In accordance with previous findings, our study confirmed 
the fact that age is the major risk factor of death for 
patients hospitalised with COVID- 19. Gender is an addi-
tional risk factor of death for patients admitted to HCUs, 
with a higher risk among older men. Comorbidities also 
play a role, with an increasing risk of death for patients 
with malignant neoplasms, cirrhosis without transplant 
and dementia in both CCUs and HCUs. These results are 
reassuring in terms of current vaccination policies that 
target older individuals. Mortality risk factors may have 
changed with successive waves of the epidemic due to 
increasing knowledge about the infection, the impact of 
preventive measures and changes in population behav-
iour. A comparison of patient characteristics between the 
successive waves of the epidemic and their association 
with severe outcomes should make it possible to assess 
the management of the crisis in France and guide subse-
quent decisions in the current context of continuous 
adaptation of policies to control the epidemic.
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